Tuesday, May 22, 2018

Atezolizumab doubles 3-year survival rate vs docetaxel in NSCLC

Even in the long term, atezolizumab shows significant survival benefit over docetaxel for patients with advanced non-small–cell lung cancer (NSCLC) who have previously been treated, regardless of PD-L1 expression levels or tumour histology, according to the POPLAR* study presented at the 2018 European Lung Cancer Congress (ELCC).

No comments:

Post a Comment

PCSK9 inhibitors show superior LDL-C lowering effects to ezetimibe

Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor is superior to ezetimibe in reducing low-density lipoprotein cholesterol (LDL-C),...